MURA – mural oncology plc - ordinary shares (US:NASDAQ)
Stock Stats
News
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Mural Oncology to Participate in Two Upcoming Investor Conferences
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Form EFFECT Mural Oncology plc
Form SC 13G/A Mural Oncology plc Filed by: ARMISTICE CAPITAL, LLC
Form SCHEDULE 13G Mural Oncology plc Filed by: Solas Capital Management, LLC
Form SCHEDULE 13G/A Mural Oncology plc Filed by: ACORN BIOVENTURES, L.P.
Form S-3 Mural Oncology plc
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.